| Literature DB >> 28887596 |
Carlos Augusto Albach1, Richard Wagland2, Katherine J Hunt2.
Abstract
PURPOSE: This systematic review (1) identifies the current generic and cancer-related patient-reported outcome measures (PROMs) that have been cross-culturally adapted to Brazilian Portuguese and applied to cancer patients and (2) critically evaluates their cross-cultural adaptation (CCA) and measurement properties.Entities:
Keywords: Brazil; Cancer; Cross-cultural adaptation; Measurement properties; Patient-reported outcome measures; Portuguese
Mesh:
Year: 2017 PMID: 28887596 PMCID: PMC5874274 DOI: 10.1007/s11136-017-1703-5
Source DB: PubMed Journal: Qual Life Res ISSN: 0962-9343 Impact factor: 4.147
Fig. 1Recommended stages for cross-cultural adaptation
(adapted from Beaton et al. [16])
Quality criteria of the cross-cultural adaptation process (adapted from Oliveira et al. [7])
| Stage | Ratinga | Quality criteria |
|---|---|---|
| I: Forward translation | + | Translations conducted by two or more independent translators |
| ? | Doubtful translation process (e.g. translators’ background or awareness status about the tool are different from the recommended, translation conducted by one translator) | |
| − | Translation conducted by two non-independent translators | |
| 0 | No information on the forward translation process | |
| II: Synthesis | + | Synthesis conducted by the same two or more translators from stage I |
| ? | Doubtful synthesis process (e.g. different translators or professionals from stage I) | |
| 0 | No information on the synthesis process | |
| III: Back-translation | + | Back-translation made by two or more independent translators for whom English is the first language and who are naive to the instrument |
| ? | Doubtful back-translation process (e.g. English is not the translators’ first language or they are aware of the instrument, back-translation conducted by one translator only) | |
| − | Back-translation made by two non-independent translators | |
| 0 | No information on back-translation process | |
| IV: Expert committee review | + | An expert committee is reported and participants’ roles clearly indicated. The committee reviews all documents |
| ? | Doubtful expert committee review (e.g. there is no mention of participants’ roles) | |
| − | The committee reviews only one or some documents | |
| 0 | No information on expert committee | |
| V: Pretesting | + | Pretest was conducted in 30 or more subjects from the target population |
| ? | Doubtful design (e.g. there is no mention of the number of subjects tested, target population not described) | |
| − | Pretest was conducted in less than 30 subjects | |
| 0 | No information on the pretest | |
| VI: Submission | + | All reports and forms were submitted to the developer of the instrument or central committee for appraisal |
| ? | Doubtful submission process (e.g. the reports and forms were received by others instead of the developer of the instrument or central committee) | |
| 0 | No information on submission process |
a + Positive rating; ? indeterminate rating; − negative rating; 0 no information available
Quality criteria for measurement properties of health-related questionnaires [23] (based on Terwee et al. [22])
| Property | Ratinga | Quality criteria |
|---|---|---|
| Reliability | ||
| Internal consistency | + | (Sub)scale unidimensional AND Cronbach’s alpha(s) ≥0.70 |
| ? | Dimensionality not known OR Cronbach’s alpha not determined | |
| − | (Sub)scale not unidimensional OR Cronbach’s alpha(s) <0.70 | |
| Measurement error | + | MIC > SDC OR MIC outside the LOA |
| ? | MIC not defined | |
| − | MIC ≤ SDC OR MIC equals or inside LOA | |
| Reliability | + | ICC/weighted Kappa ≥0.70 OR Pearson’s |
| ? | Neither ICC/weighted Kappa nor Pearson’s r determined | |
| − | ICC/weighted Kappa < 0.70 OR Pearson’s | |
| Validity | ||
| Content validity | + | The target population considers all items in the questionnaire to be relevant AND considers the questionnaire to be complete |
| ? | No target population involvement | |
| − | The target population considers items in the questionnaire to be irrelevant OR considers the questionnaire to be incomplete | |
| Construct validity | ||
| Cross-cultural validity | + | Original factor structure confirmed OR no important DIF |
| ? | Confirmation of original factor structure AND DIF not mentioned | |
| − | Original factor structure not confirmed OR important DIF | |
| Structural validity | + | Factors should explain at least 50% of the variance |
| ? | Explained variance not mentioned | |
| − | Factors explain <50% of the variance | |
| Hypothesis testing | + | (Correlation with an instrument measuring the same construct ≥0.50 OR at least 75% of the results are in accordance with the hypotheses) AND correlation with related constructs is higher than with unrelated constructs |
| ? | Solely correlations determined with unrelated constructs | |
| − | Correlation with an instrument measuring the same construct <0.50 OR < 75% of the results are in accordance with the hypotheses OR correlation with related constructs is lower than with unrelated constructs | |
| Responsiveness | ||
| Responsiveness | + | (Correlation with an instrument measuring the same construct ≥0.50 OR at least 75% of the results are in accordance with the hypotheses OR AUC ≥0.70) AND correlation with related constructs is higher than with unrelated constructs |
| ? | Solely correlations determined with unrelated constructs | |
| − | Correlation with an instrument measuring the same construct <0.50 OR < 75% of the results are in accordance with the hypotheses OR AUC < 0.70 OR correlation with related constructs is lower than with unrelated constructs | |
MIC minimal important change, SDC smallest detectable change, LOA limits of agreement, ICC intraclass correlation coefficient, DIF differential item functioning, AUC area under the curve
a+ positive rating; ? indeterminate rating; − negative rating
Fig. 2Flowchart of database search strategy and selection of studies
Characteristics of included studies
| Instrument | Instrument full-text availability | Instrument total number of items | Mean time to complete the instrument | Actual sample size (analysed data) |
|---|---|---|---|---|
| FACT-G | Yesa | 27 | NR | 975 |
| MDASI | Yesb | 19 | NR | 268 |
| VES-13 | Yesc | 13 | NR | 272 |
| EORTC QLQ-C-15-PAL | No | 15 | NR | 104 |
| SF-36 | No | 36 | NR | 106 |
| WHOQOL-bref | No | 24 | NR | 106 |
| EORTC QLQ-C30 | No | 30 | NR | 986 |
| ESAS | Yes | 10 | 2.24 min | 249 |
NR not reported
a As per request to Functional Assessment of Chronic Illness Therapy (FACIT) Group
b In a separate publication [32]
c In a separate publication [33]
d Sample size for the reliability measurement (assessed 7 to 15 days after baseline)
e Sample size for the reliability measurement (assessed 48 h after baseline)
f Sample size for the responsiveness measurement (assessed 30 days after baseline)
g Sample size for the reliability measurement (assessed 4 to 96 h after baseline)
h Sample size for the responsiveness measurement (assessed 21±7 days after baseline)
Interpretability of included studies
| Instrument | Missing scores | Description of how missing items were handled | Distribution of total scores | Respondents with the lowest possible total score | Respondents with the highest possible total score |
|---|---|---|---|---|---|
| FACT-G | 0.1 to 0.6% of non-response rate per itema | Yes | NR | NR | NR |
| MDASI | NR | NR | NR | NR | NR |
| VES-13 | NR | NR | NR | NR | NR |
| EORTC QLQ-C-15-PAL | NR | NR | NR | NR | NR |
| SF-36 | NR | NR | Yes | Yes | Yes |
| WHOQOL-bref | NR | NR | Yes | Yes | Yes |
| EORTC QLQ-C30 | 0.084% of missing items per questionnaire | No | NR | NR | NR |
| ESAS | One non-response item of out 249 questionnaires | No | Yes | NR | NR |
NR not reported
a Except for item 14 (‘satisfaction with sexual life’), which had 45% of non-response rate and was removed from the analysis
Generalisability of included studiesa
| Instrument | Age (years, mean ± SD) | Setting | Cancer stage (TNM) | Disease status | Treatment |
|---|---|---|---|---|---|
| FACT-G | 53.3 ± 13.0 | Outpatient | I–IV | Active | CT/HT/RT/IMT/ |
| MDASI | 61.5 ± 14.9 | Outpatient | III and IV: 51.8%b | Active | CT/RT/surgery |
| VES-13 | 71.6 ± 0.4 | Outpatient | NR | NR | NR |
| EORTC QLQ-C-15-PAL | 57.5 ± NR | Outpatient | IV | Active | CT/surgery were cited as the ‘most common’ used |
| SF-36 and WHOQOL-bref | 49.2 ± 9.6 | Outpatient | IV: 24.5%b | NR | CT/HT/RT/surgery |
| EORTC QLQ-C30 | 57 ± 13 | NR | NR | NR | CT/exclusive palliative care |
| ESAS | 55.1 ± 12.6 | Outpatient | “Advanced” and stage IV: 87.6% | Active | CT/RT/exclusive palliative care |
CT chemotherapy, HT hormonal therapy, IMT immunotherapy, NA not applicable, NR not reported, RT radiotherapy
a All authors used the convenience sample method, except for Paiva et al. [24] and Nunes [25] (both not reported)
b The relative percentages of other stages were not reported
c Female breast cancer population
Cross-cultural adaptation quality of generic and cancer-related Brazilian Portuguese PROMs applied for use with cancer patients
| Instrument | Pilot test sample ( | Forward translation | Synthesis | Back-translation | Expert committee review | Pretesting | Submission |
|---|---|---|---|---|---|---|---|
| FACT-Ga [ | 32 | + | + | ? | ? | + | ? |
| ESAS [ | 24 | + | ? | + | + | – | ? |
| EORTC QLQ-C30a [ | NRb | ? | ? | + | + | – | + |
| SF-36a [ | 20 | ? | + | + | ? | – | 0 |
| VES-13a [ | 33 | ? | 0 | ? | ? | + | 0 |
| MDASIa [ | NR | ? | ? | ? | ? | 0 | ? |
| EORTC QLQ-C-15-PAL [ | NR | ? | 0 | ? | – | ? | 0 |
| WHOQOL-bref [ | Unavailable data | ||||||
NR not reported
a Cross-cultural adaptation and measurement properties assessment of the instrument involved two separate publications
b Sample size was not reported. However, the EORTC quality of life translation manual recommends 10 to 15 subjects as a general rule [36]
Methodological grade and quality of the measurement properties of cancer-related and generic Brazilian Portuguese PROMs for use with cancer patients
| Instrument | Methodological grade (excellent/fair/poor)a and quality of measurement property (+/−/?)b | |||||||
|---|---|---|---|---|---|---|---|---|
| Validity | Reliability | Responsiveness | ||||||
| Content | Structural | Hypothesis testing | Internal consistency | Reliability | Measurement error | |||
| FACT-G | Methodological quality | Excellent | Excellent | Fair | Excellent | |||
| [ | Measurement quality | + | ? | – | + | |||
| MDASI | Methodological quality | Fair | Fair | |||||
| [ | Measurement quality | – | – | |||||
| VES-13 | Methodological quality | Excellent | Fair | Poor | Fair | |||
| [ | Measurement quality | + | + | – | + | |||
| EORTC QLQ-C-15-PAL | Methodological quality | Fair | Fair | Fair | ||||
| [ | Measurement quality | ? | – | – | ||||
| SF-36 | Methodological quality | Fair | Poor | Fair | Fair | Poor | ||
| [ | Measurement quality | – | ? | – | ? | – | ||
| WHOQOL-bref | Methodological quality | Fair | Poor | Fair | Fair | Poor | ||
| [ | Measurement quality | + | ? | + | ? | + | ||
| EORTC QLQ-C30 | Methodological quality | Good | Poor | |||||
| [ | Measurement quality | + | ? | |||||
| ESAS | Methodological quality | Good | Good | Poor | Poor | |||
| [ | Measurement quality | + | ? | + | ?c | |||
a Assessed using the COSMIN scale (available at www.cosmin.nl)
b + Positive rating; ? indeterminate rating; − negative rating (Table 2)
c Unknown due to distinct methodology used (Anchor-based method)